Share on Pinterest Research finds a new injectable form of PrEP is superior to daily oral tablets to prevent the contraction of HIV. Sara Jurado/Getty Images New research sheds light on the efficacy ...
Findings showed 99.9% of participants in the lenacapavir group did not acquire HIV infection. Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil ...
The findings showed that cabotegravir LA for PrEP continued to demonstrate superior efficacy in the prevention of new HIV infections among women when compared to daily oral emtricitabine/tenofovir ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback